Aurora Kinase/Cdk Inhibitor-CAS 443797-96-4-Calbiochem

半岛bd体育手机客户端 说明

一般描述

A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀= 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC₅₀= 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties bothin vitro(IC₅₀in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine modelin vivo(75-100 mg/kg, i.p.).
A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀= 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC₅₀= 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties bothin vitro(IC₅₀in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine modelin vivo(75-100 mg/kg, i.p.).

包装

5 mg in Plastic ampoule
Packaged under inert gas

生化/生理作用

Cell permeable: yes
Target IC₅₀: 11 and 15 nM for Aurora-A, Aurora-B, respectively; 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively
Product competes with ATP.
Reversible: yes
Primary Target
Aurora Kinase/Cdk

警告

Toxicity: Harmful (C)

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他说明

Emanuel, S., et al. 2005.Cancer Res.65,9038.
Lin R., et al. 2005.J. Med. Chem.48,4208.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

半岛bd体育手机客户端 性质

安全信息